

JUL 19. 2004 3:04PM

GLAXO WELLCOME

RECEIVED  
CENTRAL FAX CENTER

NO. 4342 P. 1

JUL 19 2004

**FAX**

**OFFICIAL**



GlaxoSmithKline


To 1624  
.....  
Company USPTO  
.....  
Fax 703-872-9306  
.....  
From Allyson K. Jacobs  
.....  
Tel 919-483-9105 Fax 919-483-7988  
.....  
E-mail [akj27836@glaxowellcome.com](mailto:akj27836@glaxowellcome.com)  
.....  
Date July 19, 2004 Pages including cover 9  
.....  
Subject Serial No.: 09/980,987  
.....  
Filing Date: 11/6/01  
.....

Glaxo Wellcome Inc.  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709  
Tel: 919 483 2100  
[www.gsk.com](http://www.gsk.com)

Attached:

Amendment Transmittal  
Amendment  
Certificate of Transmission

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

AMENDMENT TRANSMITTAL LETTER (Large Entity)					Docket No.	
Applicant(s): Colclough et al.					PU3611USW	
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
09/980,987	11/6/01	B. Coleman	23347	1624	2010	
Invention: 1,5-BENZODIAZEPINE DERIVATIVES						
<b>COMMISSIONER FOR PATENTS:</b>						
Transmitted herewith is an amendment in the above-identified application.						
The fee has been calculated and is transmitted as shown below.						
<b>CLAIMS AS AMENDED</b>						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	11 -	20 =	0 x	\$18.00	\$0.00	
INDEP. CLAIMS	2 -	3 =	0 x	\$86.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					\$0.00	
<input checked="" type="checkbox"/> No additional fee is required for amendment.						
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____						
<input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.						
<input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392						
<input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.						
<input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.						
 Signature			Dated: 15 July 2004			
Bonnie L. Deppenbrock, Reg. No. 28,209 Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-1577 Facsimile: (919) 483-7988						
<div style="border: 1px solid black; padding: 5px;"><p>I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p><p style="text-align: center;">_____ Signature of Person Mailing Correspondence</p><p style="text-align: center;">_____ Typed or Printed Name of Person Mailing Correspondence</p></div>						
CC:						

P11LARGE/REV07

JUL 19 2004 3:04PM

GLAXO WELLCOME

RECEIVED  
CENTRAL FAX CENTER

NO. 4342 P. 3

PU3611USW

JUL 19 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David Colclough et al.  
Application Ser. No.: 09/980,987 Art Unit: 1624  
Filing Date: 11/6/01 Examiner: B. Coleman  
Title: 1,5-BENZODIAZEPINE DERIVATIVES

---

Commissioner for Patents  
Washington, D.C. 20231

**AMENDMENT**

Sir:

This amendment is responsive to the Office Action mailed June 24, 2004.  
Please amend the attached application as follows:

Amendments to the Claims are reflected in the listing of claims which begin on  
page 2.

Remarks/Arguments begin on page 6.

PU3611USW

Complete Listing of Pending Claims

1. (Original) Enantiomerically enriched 3-{3-[1-(isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid, or a pharmaceutically acceptable salt or solvate thereof